XSHE
000590
Market cap462mUSD
Jul 15, Last price
13.86CNY
1D
0.00%
1Q
59.31%
Jan 2017
-29.47%
Name
Tus Pharmaceutical Group Co Ltd
Chart & Performance
Profile
Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 343,208 -15.18% | 404,648 15.44% | 350,528 16.54% | |||||||
Cost of revenue | 249,792 | 271,290 | 261,211 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 93,416 | 133,358 | 89,317 | |||||||
NOPBT Margin | 27.22% | 32.96% | 25.48% | |||||||
Operating Taxes | 5,092 | 4,789 | 3,704 | |||||||
Tax Rate | 5.45% | 3.59% | 4.15% | |||||||
NOPAT | 88,325 | 128,569 | 85,614 | |||||||
Net income | 25,247 39.41% | 18,110 -48.90% | ||||||||
Dividends | (4,195) | (338) | ||||||||
Dividend yield | 0.20% | 0.02% | ||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 755 | 10,000 | 38,616 | |||||||
Long-term debt | 85,204 | 86,141 | 100,352 | |||||||
Deferred revenue | 43,990 | 44,366 | ||||||||
Other long-term liabilities | 43,069 | 42,720 | 46,095 | |||||||
Net debt | (91,333) | (114,529) | (121,562) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 17,388 | (28,395) | 54,474 | |||||||
CAPEX | (22,042) | |||||||||
Cash from investing activities | 4,153 | |||||||||
Cash from financing activities | (31,513) | 111,520 | ||||||||
FCF | 81,380 | 46,970 | 45,052 | |||||||
Balance | ||||||||||
Cash | 177,292 | 189,770 | 260,530 | |||||||
Long term investments | 2 | 20,900 | ||||||||
Excess cash | 160,131 | 190,437 | 243,004 | |||||||
Stockholders' equity | 242,458 | 396,734 | 386,092 | |||||||
Invested Capital | 612,629 | 715,999 | 666,934 | |||||||
ROIC | 13.30% | 18.59% | 15.13% | |||||||
ROCE | 12.01% | 14.62% | 9.74% | |||||||
EV | ||||||||||
Common stock shares outstanding | 239,471 | 239,471 | 239,471 | |||||||
Price | 7.11 -20.65% | 8.96 0.22% | 8.94 -9.51% | |||||||
Market cap | 1,702,641 -20.65% | 2,145,663 0.22% | 2,140,873 -9.51% | |||||||
EV | 1,614,295 | 2,035,619 | 2,023,337 | |||||||
EBITDA | 122,630 | 161,399 | 113,677 | |||||||
EV/EBITDA | 13.16 | 12.61 | 17.80 | |||||||
Interest | 3,662 | 4,462 | 1,154 | |||||||
Interest/NOPBT | 3.92% | 3.35% | 1.29% |